Skip to content
OpenCapital
Get started

West Pharmaceutical Services WST Proprietary Products — R&D

Other segment segments

West Vantage
$0—

Similar metrics at other companies

Sono-Tek Corporation logo
SOTKOperating — Research Product Development
$638.5K-6.2%
Church & Dwight logo
CHDSpecialty Products Division — Research And Development Expense
$800K+33.3%
Brunswick logo
BCCorporate Segment — Research and Development Expense
$1.1M+10.0%
Vicor logo
VICRR&D
$22.29M+15.0%
Autodesk logo
ADSKR&D
$421M+6.9%
ServiceNow logo
NOWR&D
$823M+17.1%

Other financials

Income statement

See full
Revenue$844.9M+21.0%
Gross profit$296.4M+27.8%
Operating income$177.1M+65.5%
Net income$138.8M+54.6%
EPS (diluted)$1.92+56.1%

Balance sheet

See full
Cash & equivalents$521.4M+29.0%
Total debt$321.0M+4.4%
Total equity$3.0B+11.5%
Total assets$4.1B+13.6%

Cash flow

See full
Operating cash flow$89.9M-30.5%
CapEx$42.7M-40.1%
Free cash flow$47.2M-18.8%

Valuation

See full
Market cap$25.36B+64.2%
Enterprise value$25.16B+65.1%
P/E46.7×+15.1×
P/S7.9×+2.7×

Profitability

See full
Gross margin36.3%+1.7pp
Operating margin20.3%+1.2pp
Net margin16.8%+0.7pp
FCF margin14.2%+3.6pp

Returns & leverage

See full
Return on equity19.1%+1.7pp
Debt / equity0.1×0.0×
Current ratio2.7×-0.1×

Where this comes from

Reported directly by West Pharmaceutical Services in its filing.

Tagged under the XBRL concept us-gaap:ResearchAndDevelopmentExpense.

The official record: West Pharmaceutical Services’s 10-Q, filed April 23, 2026, on SEC EDGAR. View the filing →

Ask your AI about West Pharmaceutical Services's proprietary products — r&d.

Connect your AI assistant and compare segments, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is West Pharmaceutical Services's proprietary products — R&D?
West Pharmaceutical Services (WST) reported proprietary products — R&D of $15.8M in Q1 2026.
How has West Pharmaceutical Services's proprietary products — R&D changed year-over-year?
West Pharmaceutical Services's proprietary products — R&D decreased by 3.1% year-over-year, from $16.3M to $15.8M.
What is the long-term trend for West Pharmaceutical Services's proprietary products — R&D?
Over 3 years (2022 to 2025), West Pharmaceutical Services's proprietary products — R&D has grown at a 8.3% compound annual growth rate (CAGR), from $58.5M to $74.3M.
What does proprietary products — R&D mean?
This represents the expenses incurred by the proprietary products segment to develop new technologies, improve existing product designs, and innovate manufacturing processes. It is a leading indicator of the company's future competitive advantage and product pipeline.